
CEO of Sherlock Biosciences, Bryan Dechairo Discusses the Potential Diagnostic Revolution With CRISPR Diagnostics
Bryan Dechairo, the CEO of Sherlock Biosciences discusses the potential coming revolution with CRISPR diagnostics and how they could be poised to replace existing technologies such as lateral flow and PCR based testing in a number of applications. Topics discussed include the science behind CRISPR diagnostics and why it represents a significant improvement over existing technologies, the form factors for the tests under development by Sherlock including workflow, time to result, cost, and accuracy profile, manufacturing, potential commercial partners in both the retail pharmacy and physician markets, regulatory requirements for OTC tests, the intellectual property landscape in CRISPR diagnostics including potential competitor Mammoth Biosciences, the companies product pipeline in STD and infectious disease testing, potential acquirers in diagnostics for CRISPR technology, and Bryan’s vision for the future evolution of the technology.